Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

Results from the phase 2b PROCEED trial of intravenous bocunebart (also known as Lu AG09222) showed that the drug was able to cut the number of monthly migraine days (MMD) compared to placebo, with a ...

EVERSANA, a leading provider of commercialisation services to the global life sciences industry, has named Monica Avram as ...

In its main clinical trial, mRNA-1010 was shown to be 26.6% more effective than the comparator flu shot in adults aged 50 ...

In understanding what makes the patient voice so essential to successful drug development, let’s take a critical eye to what ...

According to Invest Europe, the challenge facing the European life sciences sector is clear - Europe currently accounts for ...

Private equity firm expands healthcare focus. Inflexion, a leading European mid-market private equity firm, appointed John ...

Many companies have tried to jump into the GLP-1 gold rush with their own versions of the blockbuster obesity drug. Prive Bio ...

Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...

Introducing Pharmony At this critical time, the PM Society is launching Pharmony, a positive, evidence-led response to counter the negativity and uncertainty that dominates. It’s an initiative that ...

Behind every drug and drug candidate are stories – human stories as well as scientific stories. In this interview from the sidelines of the Biotech Showcase in San Francisco last month, Alexander ...

Swiss biotech in particular saw strong activity in 2025 with the establishment of 15 new life sciences companies. In January, several Swiss life sciences start-ups announced significant financings and ...